Literatur
-
1
Jahn R.
Neuroscience. A neuronal receptor for botulinum toxin.
Science.
2006;
312
540-541
-
2
Kessler K R, Benecke R.
The EBD test – a clinical test for the detection of antibodies to botulinum toxin type A.
Mov Disord.
1997;
12
95-99
-
3
Muller K, Mix E, Adib Saberi F et al.
Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity.
J Neural Transm.
2009;
116
579-585
-
4
Yablon S A, Brashear A, Gordon M F et al.
Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
Clin Ther.
2007;
29
683-690
-
5
Dressler D, Hallett M.
Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.
Eur J Neurol.
2006;
13 (Suppl 1)
11-15
-
6
Borodic G.
Therapeutic botulinum toxin.
Lancet.
1994;
344
1370
-
7
Gracies J M, Lugassy M, Weisz D J et al.
Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study.
Arch Phys Med Rehabil.
2009;
90
9-16
-
8
Barnes M, Schnitzler A, Medeiros L et al.
Efficacy and safety of NT 201 for upper limb spasticity of various etiologies – a randomized parallel-group study.
Acta Neurol Scand.
2010;
122
295-302
-
9
Francisco G E, Boake C, Vaughn A.
Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques.
Am J Phys Med Rehabil.
2002;
8
355-363
-
10
Gracies J M, Lugassy M, Weisz D J et al.
Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study.
Arch Phys Med Rehabil.
2009;
90
9-16
-
11
Molloy F M, Shill H A, Kaelin-Lang A et al.
Accuracy of muscle localization without EMG: implications for treatment of limb dystonia.
Neurology.
2002;
58
805-807
-
12
Chin T Y, Graham H K.
Botulinum toxin A in the management of upper limb spasticity in cerebral palsy.
Hand Clin.
2003;
19
591-600
-
13
Yang E J, Rha D W, Yoo J K et al.
Accuracy of manual needle placement for gastrocnemius muscle in children with cerebral palsy checked against ultrasonography.
Arch Phys Med Rehabil.
2009;
90
741-744
-
14
Berweck S, Schroeder A S, Fietzek U M et al.
Sonographyguided injection of botulinum toxin in children with cerebral palsy.
Lancet.
2004;
363
249-250
-
15
Berweck S, Wissel J.
Sonographic imaging for guiding botulinum toxin injections in limb muscles.
Adv Clin Neurosci Rehab.
2004;
4
28-31
-
16
Berweck S, Heinen F.
Use of botulinum toxin in pediatric spasticity (cerebral palsy).
Mov Disord.
2004;
19
162-167
-
17
Fietzek U M, Schroeder A S, Wissel J et al.
Split-screen video demonstration of sonography-guided muscle identification and injection of botulinum toxin.
Mov Disord.
2010;
25
2225-2228
-
18
Ashford S, Turner-Stokes L.
Goal attainment for spasticity management using botulinum toxin.
Physiother Res Int.
2006;
11
24-34
-
19
Wissel J, Ward A B, Erztgaard P et al.
European consensus table on the use of botulinum toxin type A in adult spasticity.
J Rehabil Med.
2009;
41
13-25
-
20
Wissel J, auf dem Brinke M, Hecht M et al.
Botulinum-Neurotoxin in der Behandlung der Spastizität im Erwachsenenalter.
Nervenarzt.
2011;
82
481-495
-
21
Kanovský P, Slawek J, Denes Z et al.
Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity.
Clin Neuropharmacol.
2009;
32
259-65
-
22
Kaňovský P, Slawek J, Denes Z et al.
Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity.
J Rehabil Med.
2011;
43
486-492
-
23
Elovic E P, Brashear A, Kaelin D et al.
Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients.
Arch Phys Med Rehabil.
2008;
89
799-806
-
24
Bakheit A M, Fedorova N V, Skoromets A et al.
The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles.
J Neurol Neurosurg Psychiatry.
2004;
75
1558-1561
-
25
Mohammadi B, Balouch S A, Dengler R et al.
Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients.
Neurol Res.
2010;
32
309-313
-
26
Gordon M F, Brashear A, Elovic E et al.
Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke.
Neurology.
2004;
63
1971-1973
-
27
Lagalla G, Danni M, Reiter F et al.
Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb.
Am J Phys Med Rehabil.
2000;
79
377-384
-
28
Sutherland D H, Kaufman K R, Wyatt M P et al.
Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy.
Gait Posture.
1999;
10
1-9
-
29
Ubhi T, Bhakta B B, Ives H L et al.
Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy.
Arch Dis Child.
2000;
83
481-487
-
30
Baker R, Jasinski M, Maciag-Tymecka I et al.
Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study.
Dev Med Child Neurol.
2002;
44
666-675
-
31
Koman L A, Mooney 3 rd J F, Smith B P et al.
Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebocontrolled trial. BOTOX Study Group.
J Pediatr Orthop.
2000;
20
108-115
-
32
Wissel J, Heinen F, Schenkel A et al.
Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of „high-dose“ versus „lowdose“ treatment.
Neuropediatrics.
1999;
30
120-124
-
33
Polak F, Morton R, Ward C et al.
Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy.
Dev Med Child Neurol.
2002;
44
551-555
-
34
Heinen F, Desloovere K, Schroeder A S et al.
The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy.
Eur J Paediatr Neurol.
2010;
14
45-66
-
35
Hägglund G, Andersson S, Düppe H et al.
Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care program and new techniques to reduce spasticity.
J Pediatr Orthop B.
2005;
14
269-273
-
36
Naumann M, Albanese A, Heinen F et al.
Safety and efficacy of botulinum toxin type A following long-term use.
Eur J Neurol.
2006;
13 (Suppl 4)
35-40
-
37
Schramm A, Ndayisaba J, auf dem Brinke M et al.
Therapie der Spastik mit onabotulinumtoxin A – erweiterte praktische Erfahrungen in 10 spezialisierten deutschen Zentren.
Aktuelle Neurologie.
2011;
38
99-110
-
38
Simpson D M, Blitzer A, Brashear A et al.
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Neurology.
2008;
70
1699-1706
-
39
Poewe W, Deuschl G, Nebe A et al.
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.
J Neurol Neurosurg Psychiatry.
1998;
64
13-17
-
40
Brans J W, Lindeboom R, Snoek J W et al.
Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial.
Neurology.
1996;
46
1066-1072
-
41
Benecke R, Jost W H, Kanovsky P et al.
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.
Neurology.
2005;
64
1949-1951
-
42
Brashear A, Hogan P, Wooten-Watts M et al.
Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia.
Advances in Therapy.
2005;
22
49-55
-
43
Haussermann P, Marczoch S, Klinger C et al.
Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.
Movement Disorders.
2004;
19
303-308
-
44
Truong D, Brodsky M, Lew M et al.
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Parkinsonism Relat Disord.
2010;
16
316-323
-
45
Mohammadi B, Buhr N, Bigalke H et al.
A long-term follow-up of botulinum toxin A in cervical dystonia.
Neurol Res.
2009;
31
463-466
-
46
Reichel G, Stenner A, Jahn A.
Zur Phänomenologie der zervikalen Dystonien.
Fortschr Neurol Psychiatr.
2009;
77
272-277
-
47
Roggenkämper P, Jost W H, Bihari K et al.
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.
J Neural Transm.
2006;
113
303-312
-
48
Jankovic J, Comella C, Hanschmann A et al.
Efficacy and safety of incobotulinumtoxin A in the treatment of blepharospasm – A randomized trial.
Mov Disord.
2011;
26
1521-1528
-
49
Wabbels B, Reichel G, Fulford-Smith A et al.
Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm.
J Neural Transm.
2011;
118
233-239
-
50
Mejia N I, Vuong K D, Jankovic J.
Long-term botulinum toxin efficacy, safety, and immunogenicity.
Mov Disord.
2005;
20
592-597
-
51
Hsiung G Y, Das S K, Ranawaya R et al.
Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.
Mov Disord.
2002;
17
1288-1293
-
52
Bentivoglio A R, Fasano A, Ialongo T et al.
Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.
Neurotox Res.
2009;
15
224-231
-
53
Truong D, Comella C, Fernandez H H et al.
Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial.
Parkinsonism Relat Disord.
2008;
14
407-414
-
54
Albanese A, Bentivoglio A R, Colosimo C et al.
Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients.
J Neurol Neurosurg Psych.
1996;
60
693-694
-
55
Jankovic J, Schwartz K, Clemence W et al.
A randomized, double-blind, placebocontrolled study to evaluate botulinum toxin type A in essential hand tremor.
Mov Disord.
1996;
11
250-256
-
56
Brin M F, Lyons K E, Doucette J et al.
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.
Neurology.
2001;
56
1523-1528
-
57
Naumann M, So Y, Argoff C E et al.
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Neurology.
2008;
70
1707-1714
-
58
Naumann M, Lowe N J.
Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial.
BMJ.
2001;
323
596-599
-
59
Heckmann M, Ceballos-Baumann A O, Plewig G.
Botulinum toxin A for axillary hyperhidrosis (excessive sweating).
N Engl J Med.
2001;
344
488-493
-
60
Lipp A, Trottenberg T, Schink T et al.
A randomized trial of botulinum toxin A for treatment of drooling.
Neurology.
2003;
61
1279-1281
-
61
Aurora S K, Dodick D W, Turkel CC et al.
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Cephalalgia.
2010;
30
793-803
-
62
Diener H C, Dodick D W, Aurora S K et al.
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
Cephalalgia.
2010;
30
804-814
-
63
Blumenfeld A, Silberstein S D, Dodick D W et al.
Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program.
Headache.
2010;
50
1406-1418
-
64
Dykstra D D, Sidi A A.
Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study.
Arch Phys Med Rehabil.
1990;
71
24-26
-
65
Seze de M, Petit H, Gallien P et al.
Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease.
Eur Urol.
2002;
42
56-62
Prof. Dr. med. Jörg Wissel
Neurologische Rehabilitationsklinik Beelitz-Heilstätten
Paracelsusring 6a
14547 Beelitz-Heilstätten
Email: joerg@schwarz-wissel.de
